A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
City of Hope Medical Center
University of Turin, Italy
Roswell Park Cancer Institute
Mayo Clinic
Mayo Clinic
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
Augusta University
Washington University School of Medicine
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
University of California, San Francisco
Hackensack Meridian Health
Essen Biotech
M.D. Anderson Cancer Center
Mayo Clinic
University of Arkansas
Medical College of Wisconsin
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
University of Leeds
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Northside Hospital, Inc.
Brown University
University of Rochester
Affiliated Hospital to Academy of Military Medical Sciences
GWT-TUD GmbH
Case Comprehensive Cancer Center
University of Arkansas
Mayo Clinic
Mayo Clinic
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
University of Arkansas
University of Arkansas
University of Pennsylvania
City of Hope Medical Center
City of Hope Medical Center